UroGen Pharma Q1 2025: JELMYTO revenue $20.3M, net loss widens to $43.8M; UGN-102 PDUFA June 13

UroGen Pharma Ltd.

JELMYTO net sales $20.3M (+8% YoY); underlying demand grew 12%.
Net loss of $43.8M ($0.92 per share) vs $32.3M ($0.87) in Q1 2024.
Cash and marketable securities $200.4M; FY2025 JELMYTO revenue guidance unchanged at $94–$98M.
UGN-102 NDA under FDA review; PDUFA target action date June 13, 2025; ODAC meeting May 21.
UGN-501 acquisition from IconOVir expensed; UGN-103 Phase 3 UTOPIA trial enrollment to complete mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.